𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?

✍ Scribed by Francis Y. Yao; Stefan Breitenstein; Christoph E. Broelsch; Jean-Francois Dufour; Morris Sherman


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
96 KB
Volume
17
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


We searched the MEDLINE database (PubMed) and the Cochrane Library to identify studies evaluating down-staging and locoregional therapy for hepatocellular carcinoma (HCC) before liver transplantation (LT). The search was restricted to studies written in English and published from 1995 to 2010. The key words for the search included down-staging, liver transplantation, hepatocellular carcinoma, locoregional therapy, staging, treatment outcomes, radio frequency ablation, and transarterial chemoembolization. All published articles and abstracts were reviewed and screened by 2 members of the working group independently (F.Y.Y. and S.B.), and relevant articles and abstracts were selected for further review by the group. The group agreed on 5 key questions for addressing this topic, and each of the 5


πŸ“œ SIMILAR VOLUMES


Down-staging of hepatocellular carcinoma
✍ Matteo Ravaioli; Gian Luca Grazi; Matteo Cescon; Franco Trevisani; Fabio Piscagl πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 44 KB πŸ‘ 1 views

We enjoyed the article by Yao et al. in the recent issue of HEPATOL-OGY 1 in which they report an excellent outcome of liver transplantation (LT) following preoperative down-staging of hepatocellular carcinoma (HCC). Yao et al. selected HCCs without vascular invasion by imaging studies and out of t

Liver transplantation outcomes for early
✍ Jessica Y. Leung; Andrew X. Zhu; Fredric D. Gordon; Daniel S. Pratt; Abigail Mit πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 341 KB πŸ‘ 2 views

The incidence of hepatocellular carcinoma (HCC), a frequent and incurable complication of cirrhosis, continues to rise. Orthotopic liver transplantation (OLT) has been proposed as a treatment for unresectable, intrahepatic HCC limited in extent to the Milan criteria adopted by the United Network of

Tools for monitoring patients with hepat
✍ Norman Kneteman; Tito Livraghi; David Madoff; Eduardo de SantibaΓ±ez; Michael Kew πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 192 KB

For patients who are initially being listed for liver transplantation and for patients who are seeking to retain their active status on the wait list, the first step in the diagnostic consideration of hepatocellular carcinoma (HCC) is the accurate identification and staging of the tumors. Advances i

What is the best staging system for hepa
✍ Kim M. Olthoff; Alejandro Forner; Stefan HΓΌbscher; John Fung πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 1 views

The purposes of cancer staging are (1) to accurately predict a patient's prognosis and (2) to determine the appropriate interventions. Hepatocellular carcinoma (HCC) is somewhat unique: it usually affects patients with underlying liver disease, and both tumor burden and liver function need to be car

Optimizing staging for hepatocellular ca
✍ Richard B. Freeman; Abigail Mithoefer; Robin Ruthazer; Khanh Nguyen; Anthony Sch πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 1 views

Assignment of liver allocation priority for hepatocellular carcinoma is predicated on accurate imaging staging. We analyzed radiographically defined stage (radiologic stage [RS]) at listing and most recent extension and pathologic stage (PS) data from 789 liver transplant recipients for whom no pret

A new priority policy for patients with
✍ Fabio Piscaglia; Valeria Camaggi; Matteo Ravaioli; Gian Luca Grazi; Matteo Zanel πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 188 KB πŸ‘ 1 views

The best prioritization of patients with hepatocellular carcinoma (HCC) waiting for liver transplantation under the model for end-stage liver disease (MELD) allocation system is still being debated. We analyzed the impact of a MELD adjustment for HCC, which consisted of the addition of an extra scor